Has Wayne Levy received payments from drug or device companies?

Yes. Drug and device makers reported $275,410 in general payments to Wayne Levy across 221 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wayne Levy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wayne Levy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wayne Levy

Advanced Heart Failure and Transplant Cardiology · Seattle, WANPI 1679663538

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $260,166 of the $275,410 with a category attached, or 94.5%. Abbott accounts for 65.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $82,666 and has fallen 82.4% since, to $14,550 in 2025. Among advanced heart failure and transplant cardiology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$275,410in general payments, 2019–2025

Across 221 payments — averaging $1246.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$180K
Medtronic$69K
Kestra Medical Technology Services, Inc.$10K
Impulse Dynamics (USA) Inc.$9K
Livanova USA, Inc.$4K
ZOLL Respicardia, Inc.$3K

$120,259in research payments, 2019–2025

Across 18 payments — averaging $6681.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Beckman Coulter, Inc.$54K
Medtronic$50K
Novartis$16K

What the payments were for

Consulting fees$260,16694%
Speaking & faculty fees$6,5082%
Travel & lodging$5,3132%
Food & beverage$3,4231%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	170	$179,764
Medtronic(2 entities)	29	$69,252
Kestra Medical Technology Services, Inc.	4	$9,950
Impulse Dynamics (USA) Inc.	4	$9,225
Livanova USA, Inc.	8	$4,460
ZOLL Respicardia, Inc.	6	$2,760

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CardioMEMS HF System$138,478
CARDIOMEMS$29,125
OPTIMIZER$16,950
Assure WCD$9,950
VNS - Vitaria$4,460
remede System$2,631
HeartWare HVAD$1,500
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,125
OPTIMIZER SMART SYSTEM$750

How this compares

$275,410 in reported general payments places this provider in the 95th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

See all advanced heart failure and transplant cardiology providers in Washington →

Medicare billing

Part B allowed, 2024

$90,298

Medicare patients

1,309

Services billed

2,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VyndamaxTafamidis	12	$268,066
EntrestoSacubitril/Valsartan	40	$74,899
EliquisApixaban	54	$73,138
JardianceEmpagliflozin	34	$43,356
FarxigaDapagliflozin Propanediol	13	$21,243
Sirolimus	33	$11,887
Tacrolimus	102	$6,570
Eplerenone	37	$2,699
Mycophenolate Mofetil	32	$1,650
Valsartan	52	$1,633
Ezetimibe	74	$1,336
Pravastatin Sodium	37	$904
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	85	$852
Carvedilol	86	$852
Atorvastatin Calcium	92	$848

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Seattle

John MignoneSeattle$19K
Preethi PirlamarlaSeattle$14K
Salpy PamboukianSeattle$5K
James ZhangSeattle$3K
April Stempien OteroSeattle$2K
Sunu ThomasSeattle$2K
Richard ChengSeattle$759
Elina MinamiSeattle$698
Daniel FishbeinSeattle$600
Kevin ObrienSeattle$222

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →